Glatiramer Acetate 40 mg/mL (Glatiramer INJECTION, SOLUTION) 40 mg/mL

Glatiramer Acetate 40 mg/mL is a subcutaneous injection solution used for managing specific neurological conditions. This medication is designed to support immune system modulation and is available in convenient packaging.

Strength

40 mg/mL

Pack Size

12 BLISTER PACK in 1 CARTON (0378-6961-12) / 1 SYRINGE in 1 BLISTER PACK (0378-6961-32) / 1 mL in

Manufacturer / TM Owner

Mylan Pharmaceuticals Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Glatiramer Acetate 40 mg/mL is primarily used for the treatment of relapsing forms of multiple sclerosis. It works by modulating the immune system to reduce the frequency of relapses. This medication is often prescribed to individuals diagnosed with this condition to help manage symptoms and slow disease progression.

Side Effects

Common effects of Glatiramer Acetate 40 mg/mL may include injection site reactions, such as redness, swelling, or itching. Some users might experience flu-like symptoms, including fever, chills, or fatigue. These effects are generally mild and temporary.

Precautions & Warnings

Glatiramer Acetate 40 mg/mL should be stored at room temperature and protected from light. It is important to use this medication exactly as directed by a healthcare provider. Always check the solution for particles or discoloration before use.

Avoid Interactions

Glatiramer Acetate 40 mg/mL may interact with other medications, including those that affect the immune system. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements may also affect the efficacy of this medication.

References

Frequently Asked Questions

Glatiramer Acetate 40 mg/mL is used to manage relapsing forms of multiple sclerosis by modulating the immune system.

Glatiramer Acetate 40 mg/mL is administered via subcutaneous injection, typically into the thigh, abdomen, or upper arm.

Common side effects include injection site reactions, flu-like symptoms, and fatigue.

It is important to consult a healthcare provider before combining Glatiramer Acetate 40 mg/mL with other medications to avoid potential interactions.

Glatiramer Acetate 40 mg/mL should be stored at room temperature and protected from light.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.